Group 1 - The core viewpoint of the article is that HaiXin Co., Ltd. is progressing with the APDC Phase III clinical trial project through its subsidiary HaiXin Bio [2] Group 2 - HaiXin Co., Ltd. responded to investor inquiries on an interactive platform regarding the status of its clinical trial [2] - The APDC Phase III clinical trial is still ongoing, indicating continued development efforts in the company's biopharmaceutical initiatives [2]

Group 1 - The core point of the article is that HaiXin Co., Ltd. (600851.SH) has confirmed that its subsidiary, HaiXin Bio, is continuing to advance the Phase III clinical trial project for APDC [1] Group 2 - The company is actively engaging with investors through its interactive platform to provide updates on its clinical trial progress [1]

Group 1 - The core viewpoint of the article highlights the recent developments in HaiXin Co., Ltd.'s pharmaceutical sector, particularly in the area of oncology drug research and development [1] - The chairman of HaiXin Co., Ltd., Deng Haibin, stated that the company's pharmaceutical subsidiaries are primarily traditional generic drug companies, focusing on post-marketing clinical trial evaluations of existing key products and promoting the consistency evaluation of generic drugs [1] - Regarding the clinical trial progress of HaiXin Biotech's APDC, it was mentioned that the design of the Phase III clinical trial was established a long time ago, leading to difficulties in patient enrollment, and the company is currently exploring solutions to this issue [1]